While the use of cannabis extracts instead of raw plant material reduces many risks associated with smoking, cannabis concentrates can pose different health hazards if they are not free of the organic solvents, oftentimes referred to as residual solvents, used in the extraction process. Residual solvents remaining in medicinal products can potentially cause adverse health effects including cancer, reproductive harm, damage to the nervous system, lungs, kidneys, and liver. Therefore, Pennsylvania requires testing of medical cannabis concentrate products for residual solvent levels to ensure safe consumption.
US Cannalytics is dedicated to ensuring the safety of medical cannabis extracts by using advanced gas chromatography mass spectrometry (GC-MS) instrumentation to accurately quantify residual solvents in the parts per million (ppm) range.
We utilize ISO-accredited methods to analyze medical cannabis concentrates and CBD products for:
Don’t see what you’re looking for? Please contact us for custom analyses!